Top

Published in:

01-12-2015 | Breast Oncology

Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer

Authors: Erik Liederbach, BS, Chi-Hsiung Wang, PhD, Waseem Lutfi, BS, Olga Kantor, MD, Catherine Pesce, MD, David J. Winchester, MD, Katharine Yao, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2015

Abstract

Background

Studies have shown that contralateral breast cancer (CBC) portends worse survival compared to unilateral breast cancer (UBC), but few studies have been conducted in the United States, and survival is usually examined from the time of CBC development.

Methods

Utilizing the Surveillance, Epidemiology, and End Results database, we selected 83,001 newly diagnosed breast cancer patients from 1998 to 2005. The time interval between the initial cancer and CBC was used as a time-dependent variable in a Cox regression analysis to examine overall survival (OS) and disease-specific survival (DSS) between UBC and CBC.

Results

Overall, 2130 patients (2.6 %) developed a CBC, 47.2 % within 5 years and 52.8 % ≥5 years. Most stage I patients (61.9 %) developed a stage I CBC, and a majority of stage II patients (51.6 %) developed a stage I CBC (p < 0.001). There was a median follow-up of 8.7 years. After adjustment, patients who developed a CBC 4 years after their initial breast cancer had worse DSS compared to patients with UBC (hazard ratio 1.36, 95 % confidence interval 1.03–1.79). Those patients who developed their CBC 8 years after their initial breast cancer had improved DSS (hazard ratio 0.37, 95 % confidence interval 0.20–0.67). Similar trends were observed for OS. Similar trends for OS and DSS were observed for estrogen receptor–negative women and women <50 years old.

Conclusions

Development of a CBC early is associated with worse survival, but CBC development later on is associated with improved survival. Future studies are needed that can assist physicians with how to predict whether a patient will develop a CBC early on.

Hou N, Huo D. A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Res Treat. 2013;138:633–41.PubMedCrossRef

Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564–9.PubMedPubMedCentralCrossRef

Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56:1038–45.PubMedCrossRef

Lizarraga IM, Sugg SL, Weigel RJ, et al. Review of risk factors for the development of contralateral breast cancer. Am J Surg. 2013;206:704–8.PubMedCrossRef

Yao K, Stewart AK, Winchester DJ, et al. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol. 2010;17:2554–62.PubMedCrossRef

Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.PubMedCrossRef

Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–7.PubMedCrossRef

Arrington AK, Jarosek SL, Virnig BA, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16:2697–704.PubMedCrossRef

Tracy MS, Rosenberg SM, Dominici L, et al. Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research. Breast Cancer Res Treat. 2013;140:447–52.PubMedCrossRef

10.

Pesce CE, Liederbach E, Czechura T, et al. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. J Am Coll Surg. 2014;219:19–28.PubMedCrossRef

11.

Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159:373–81.PubMedPubMedCentralCrossRef

12.

Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17:2702–9.PubMedPubMedCentralCrossRef

13.

Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:401–9.PubMedPubMedCentralCrossRef

14.

Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118:5637–43.PubMedPubMedCentralCrossRef

15.

Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a Cancer Research Network project. J Clin Oncol. 2005;23:4275–86.PubMedCrossRef

16.

Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst. 2014;106(8):1–7.CrossRef

17.

Kruper L, Kauffmann RM, Smith DD, et al. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. Ann Surg Oncol. 2014;21:3448–56.PubMedCrossRef

18.

Yao K, Winchester DJ, Czechura T, et al. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002. Breast Cancer Res Treat. 2013;142:465–76.PubMedCrossRef

19.

Pesce C, Liederbach E, Wang C, et al. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor–negative breast cancer. Ann Surg Oncol. 2014;21:3231–9.PubMedCrossRef

20.

Kuo WH, Yen AM, Lee PH, et al. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer. 2009;100:563–70.PubMedPubMedCentralCrossRef

21.

Hartman M, Czene K, Reilly M, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25:4210–6.PubMedCrossRef

22.

Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110:189–97.PubMedPubMedCentralCrossRef

23.

Shi YX, Xia Q, Peng RJ, et al. Comparison of clinicopathologic characteristics and prognoses between bilateral and unilateral breast cancer. J Cancer Res Clin Oncol. 2012;138:705–14.PubMedCrossRef

24.

Alkner S, Bendahl PO, Ferno M, et al. Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer. 2011;11:114.PubMedPubMedCentralCrossRef

25.

Vichapat V, Garmo H, Holmqvist M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol. 2012;30:3478–85.PubMedCrossRef

26.

Vichapat V, Garmo H, Holmberg L, et al. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat. 2011;130:609–18.PubMedCrossRef

27.

Verkooijen HM, Chatelain V, Fioretta G, et al. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat. 2007;105:347–57.PubMedCrossRef

28.

Font-Gonzalez A, Liu L, Voogd AC, et al. Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. Breast Cancer Res Treat. 2013;139:811–9.PubMedCrossRef

29.

Carmichael AR, Bendall S, Lockerbie L, et al. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28:388–91.PubMedCrossRef

30.

Mose S, Adamietz IA, Thilmann C, et al. Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol. 1997;20:541–5.PubMedCrossRef

31.

Takahashi H, Watanabe K, Takahashi M, et al. The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer. 2005;12:196–202.PubMedCrossRef

32.

Abdalla I, Thisted RA, Heimann R. The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J. 2000;6:266–72.PubMed

33.

Quan G, Pommier SJ, Pommier RF. Incidence and outcomes of contralateral breast cancers. Am J Surg. 2008;195:645–50.PubMedCrossRef

34.

National Cancer Institute. Overview of the SEER Program, 2015. Available at: http://seer.cancer.gov/about/overview.html. Accessed 14 Apr 2015.

35.

World Health Organization. International classification of disease for oncology. 3rd ed. Geneva: World Health Organization; 2000.

36.

Liederbach E PR, Hughes K, Watkin R, Wang C, Yao K. Clinicopathologic features and time interval analysis of contralateral breast cancers. Surgery. In press.

37.

Mariotto A, Feuer EJ, Harlan LC, et al. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst. 2002;94:1626–34.PubMedCrossRef

38.

Abbott A, Rueth N, Pappas-Varco S, et al. Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol. 2011;18:3129–36.PubMedCrossRef

39.

Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.PubMedPubMedCentralCrossRef

Title: Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer
Authors: Erik Liederbach, BS
Chi-Hsiung Wang, PhD
Waseem Lutfi, BS
Olga Kantor, MD
Catherine Pesce, MD
David J. Winchester, MD
Katharine Yao, MD
Publication date: 01-12-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-015-4835-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 3/2015

Surgical Management of Breast Cancer in 2010–2011 SEER Registries by Hormone and HER2 Receptor Status

An International Multicenter Review of the Malignancy Rate of Excised Papillomatous Breast Lesions

Adjuvant Chemotherapy and Radiation Therapy is Associated with Improved Survival for Patients with Extrahepatic Cholangiocarcinoma

Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience

Factors Predictive of Emergency Department Visits and Hospitalization Following Thyroidectomy and Parathyroidectomy

Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis